Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Hadassah Cardiologists Initiate International Heart Valve Summit

As members of an international consortium of leading scientists studying the heart’s mitral valve, Hadassah Medical Center cardiologists invited their colleagues to meet in Jerusalem for a first International Heart Valve Summit of the Israel Heart Society.

Prof. Chaim Lotan, Director Hadassah Heart Institute

The consortium, under the aegis of the LeDucq Foundation, was founded by French Entrepreneur Jean LeDucq and his wife Sylviane, with the mission of bringing together international experts to combat cardiovascular and neurovascular disease.

Over 200 cardiologists and many cardiac paraprofessionals attended the meeting. The speakers included Dr. Hal Dietz from Baltimore’s John Hopkins Hospital, who discovered the manner in which the gene for Marfan Syndrome, a connective tissue disorder, leads to disease, resulting in a revolution in the treatment of the syndrome; Dr.  Alain Carpentier, a pioneer in catheter-based aortic valve replacement, Adjunct Professor of Cardiothoracic Surgery at Mount Sinai Hospital in New York, and Professor of Cardiovascular Surgery at Hopital Européen Georges Pompidou in Paris; and Dr. Robert Levine, Senior Physician, Massachusetts General Hospital, Boston, who gave a presentation on the biology of the mitral leaflet (the flaps of the valve). Prof. Chaim Lotan, head of Hadassah’s Heart Institute, shared his work on the biological mechanisms that lead to valve calcification and dysfunction.

As a direct result of the meeting, Hadassah began a collaborative research project involving a Muslim Arab family whose members have a genetic form of early onset malignant valve calcification, which leads to early death. Prof. Lotan relates that “we plan in the very near future to clone the genetic mutation and, potentially, find a cure.”

Prof. Lotan adds: “By forging scientific alliances that transcend national borders and promoting the education of young researchers who thrive in an international context, we hope to be able to promote innovative research, an efficient use of research resources, and the development of long-term collaborative relationships that will allow us to continue to meet the challenges of cardiovascular disease in the future.”

Date: 9/27/2012

More hMedicine Stories

Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America